Nine Diagnostics
- Company typePrivate
- Founded2024
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Nine Diagnostics firmographics
Firmographics- Name
- Nine Diagnostics
- Legal name
- Nine Diagnostics
- Website
- https://ninediagnostics.xyz
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Nine Diagnostics industry classification
Industry- Product category
- Precision Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
Keywords
Where Nine Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Nine Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Platform Licensing: The company develops and commercializes its AI-enabled nanosensor diagnostic platform. Revenue is expected to come from licensing the technology to healthcare providers, pharmaceutical companies, and diagnostic laboratories. The platform supports both early detection and treatment monitoring applications.
- Biomarker and Diagnostic Services: Providing diagnostic services using the nanosensor platform for cancer detection and treatment monitoring. The platform enables clinicians to access earlier markers for treatment effectiveness.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Nine Diagnostics product offering
Product offeringCore offering
Nine Diagnostics develops an AI-enabled nanosensor diagnostic platform that uses fluorescent carbon nanotube sensors to detect molecular fingerprints in small patient samples (e.g., blood serum). Machine learning algorithms decode these molecular fingerprints into clinically actionable insights for cancer detection, treatment selection, dosing optimization, and real-time treatment effectiveness monitoring. The platform integrates multidimensional health data including clinical, environmental, and social factors to create holistic patient profiles.
Product overview
Nine Diagnostics offers a unified AI-enabled nanosensor platform that combines fluorescent carbon nanotube sensing technology with machine learning algorithms. The core platform captures multidimensional molecular fingerprints from small-volume patient samples (such as blood serum) and processes them through machine perception systems to detect disease states and treatment effectiveness. The Molecular Fingerprinting Platform generates the sensor data, while the Machine Learning-Driven Diagnostic Platform translates these patterns into actionable clinical insights. The platform is designed for oncology applications including early cancer detection, treatment selection optimization, and disease monitoring.
Differentiator
Problem solved
Functional benefit
Products and services
- AI-Enabled Nanosensor Diagnostic Platform A proprietary diagnostic platform combining fluorescent carbon nanotube nanosensors with machine learning pattern recognition to analyze biological samples (e.g., blood serum) at the molecular level, capturing real-time multidimensional health profiles for oncology applications including early cancer detection, treatment selection, dosing optimization, and treatment response monitoring. Targeted at oncologists, cancer researchers, pharmaceutical developers, and clinical research institutions.
Quantifiable outcome
- Every 4-week delay in cancer treatment causes up to 28% increase in mortality risk - Nine Diagnostics' faster feedback loops can reduce this delay
- +1 more outcomes
Companies that use Nine Diagnostics
Customer profileSegments3 records
Ideal customer profiles3 records
Nine Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Nine Diagnostics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered major, core and minor.
- SCbiomajorNine Diagnostics is participating in the Spring 2026 DRIVE Accelerator Biomarkers and Diagnostics track, run by SCbio in partnership with MassBio. The program brings together emerging companies developing next-generation diagnostic and biomarker technologies, with access to industry mentors and ecosystem partners including Eli Lilly, LabCorp, and other strategic partners focused on accelerating clinical translation.
- MassBiomajorPartnership through DRIVE Accelerator providing Nine Diagnostics with access to industry mentors, ecosystem partners, and potential commercialization pathways in the biomarkers and diagnostics space.
- Weill Cornell MedicinecoreCo-founders Daniel Heller and Mijin Kim are part of the Weill Cornell Medicine team led by Lish Ndhlovu contributing to the ARPA-H LIGHT program. This program advances the ability to measure and interpret signals from the lymphatic system using AI-enabled nanosensor technologies, with potential applications in cancer progression, treatment response, and recurrence monitoring.
- Orbits OncologycoreNine Diagnostics and Orbits Oncology have executed a Letter of Intent to jointly develop a next-generation precision oncology diagnostics platform. The partnership combines Nine's nanosensor-based molecular fingerprinting platform with Orbit Oncology's organoid-based functional drug-response platform, enabling a closed-loop view of disease state and therapeutic efficacy. Initial focus on lung cancer and renal cell carcinoma with integrated workflow development and multimodal dataset generation.
- American Cancer Society BrightEdgemajorNine Diagnostics joined the American Cancer Society's BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate promising oncology-focused startups. The program provides access to top-tier mentorship, investment opportunities, and strategic industry connections to support innovation in cancer treatment selection, dosing, optimization, and monitoring.
- Netherlands Innovation NetworkminorU.S.-Dutch Consortium Collaboration in Women's Health supported by the Netherlands Innovation Network in Boston and Dutch Ministry of Economic Affairs. Building novel solutions for women's health through diagnostic tools and treatments development with leading Dutch and U.S. companies.
- Merck Digital Sciences StudiomajorNine Diagnostics was selected for Merck Digital Sciences Studio Cohort 3, receiving strategic guidance, direct investment, and connection opportunities within Merck. The 10-month accelerator program provides mentorship, workshops, office space, and up to $150,000 Azure Cloud computing credits. Collaboration with Merck to advance the AI-enabled nanosensor platform.
- LabCentralmajorNine Diagnostics was awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, hosted by the Novo Nordisk Bio Innovation Hub. The award provides lab space, mentorship, and collaboration opportunities in LabCentral's vibrant and collaborative environment. LabCentral is a nonprofit launchpad supporting life sciences and biotech startups in Cambridge, MA.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Nine Diagnostics competitors and assessment
Company assessmentDirect peers
- Freenome: Freenome is a multiomics blood-based early cancer detection platform using machine learning on cell-free DNA and other biomarkers. Directly comparable to Nine Diagnostics as both target biomarker-agnostic, ML-driven liquid biopsy diagnostics for early cancer detection.
- GRAIL: GRAIL's Galleri multi-cancer early detection test uses methylation-based cfDNA sequencing with ML. Highly comparable as a blood-based, AI-enabled early cancer screening platform targeting asymptomatic and high-risk populations.
- Orbits Oncology: Orbits Oncology is Nine Diagnostics' LOI partner developing an organoid-based functional drug-response platform. Highly comparable as a functional precision medicine company and immediate integration partner in the closed-loop diagnostics workflow.
- Thrive Earlier Detection: Thrive Earlier Detection (acquired by Exact Sciences) developed the CancerSEEK multi-analyte blood test combining cfDNA and protein biomarkers with ML. A direct comparator for early cancer detection via integrated multi-analyte liquid biopsy.
Broad incumbents
- Guardant Health: Guardant Health provides liquid biopsy tests across screening, recurrence monitoring, and tumor profiling using cfDNA NGS. A well-established incumbent whose product portfolio overlaps Nine Diagnostics' oncology liquid biopsy and treatment monitoring use cases.
- Exact Sciences: Exact Sciences (Cologuard, Oncotype DX) is a diagnostics incumbent expanding into liquid biopsy via Thrive Earlier Detection. Broadly comparable as a cancer screening and treatment selection diagnostics company leveraging novel molecular approaches.
- Natera: Natera develops cell-free DNA tests including Signatera for MRD monitoring and Vantage for multi-cancer screening. An incumbent comparable on treatment monitoring and recurrence detection use cases that compete with Nine Diagnostics' platform.
- Foundation Medicine: Foundation Medicine (Roche) provides comprehensive genomic profiling and liquid biopsy services for oncology treatment selection. Comparable as a precision oncology diagnostics leader with broad pharma partnerships in companion diagnostics.
Emerging players
- Adela: Adela is developing a blood-based multi-cancer screening platform using methylation enrichment and ML. An emerging peer sharing the biomarker-agnostic, ML-driven liquid biopsy thesis that targets broad cancer detection.
- Predicine: Predicine offers cfDNA/cfRNA-based liquid biopsy tests for tumor profiling and MRD with proprietary NGS assays. Comparable emerging player offering blood-based diagnostics for precision oncology similar to Nine Diagnostics' positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Nine Diagnostics social profiles
Digital presenceNine Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nine Diagnostics leadership team
Management profileNumber of profiles
Profiles5 records
Nine Diagnostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nine Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nine Diagnostics
What does Nine Diagnostics do?
Nine Diagnostics develops an AI-enabled nanosensor diagnostic platform that uses fluorescent carbon nanotube sensors to detect molecular fingerprints in small patient samples (e.g., blood serum). Machine learning algorithms decode these molecular fingerprints into clinically actionable insights for cancer detection, treatment selection, dosing optimization, and real-time treatment effectiveness monitoring. The platform integrates multidimensional health data including clinical, environmental, and social factors to create holistic patient profiles.
Is Nine Diagnostics a public or private company?
Nine Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nine Diagnostics founded?
Nine Diagnostics was founded in 2024. It employs 1 to 10 people.
Where is Nine Diagnostics based?
Nine Diagnostics is headquartered in Cambridge, United States, in the North America region.
How does Nine Diagnostics make money?
Two revenue lines are on record. Diagnostic Platform Licensing is the primary driver. The others are biomarker and Diagnostic Services.
Who are Nine Diagnostics's main competitors?
Direct peers on record are Freenome, GRAIL, Orbits Oncology and Thrive Earlier Detection. Broad incumbents are Guardant Health, Exact Sciences, Natera and Foundation Medicine. Emerging players are Adela and Predicine.
Does Nine Diagnostics have an API?
No public API is recorded for Nine Diagnostics.
What industry is Nine Diagnostics in?
Nine Diagnostics's product category is Precision Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 325413 and its SIC code is 2835.